Apnimed (NASDAQ:APMD) Stock Price Up 6.2% – Here’s Why

Apnimed, Inc. (NASDAQ:APMD – Get Free Report) shot up 6.2% during trading on Tuesday. The company traded as high as $17.32 and last traded at $17.29. Approximately 141,006 shares were traded during trading, a decline of 69% from the average daily volume of 449,775 shares. The stock had previously closed at $16.28.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on APMD. Zacks Research upgraded shares of Apnimed to a “hold” rating in a research report on Wednesday, August 26th. Lifesci Capital began coverage on shares of Apnimed in a research note on Tuesday, August 25th. They set an “outperform” rating and a $50.00 target price on the stock. Bank of America started coverage on shares of Apnimed in a research note on Tuesday, August 25th. They set a “buy” rating and a $41.00 target price on the stock. Cantor Fitzgerald began coverage on shares of Apnimed in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price for the company. Finally, Weiss Ratings initiated coverage on Apnimed in a report on Tuesday, October 27th. They set a “sell (e-)” rating on the stock. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.33.

View Our Latest Research Report on Apnimed

Apnimed Stock Down 1.1%

The business’s 50-day moving average is $19.86. The company has a market cap of $718.13 million and a price-to-earnings ratio of 6.56.

Apnimed (NASDAQ:APMD – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($1.05) earnings per share for the quarter. The firm had revenue of $2.48 million for the quarter. Equities research analysts anticipate that Apnimed, Inc. will post -0.24 earnings per share for the current year.

Institutional Investors Weigh In On Apnimed

A hedge fund recently bought a new stake in Apnimed stock. Integral Health Asset Management LLC bought a new stake in shares of Apnimed, Inc. (NASDAQ:APMD – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 225,000 shares of the company’s stock, valued at approximately $4,930,000. Integral Health Asset Management LLC owned 0.54% of Apnimed as of its most recent filing with the Securities and Exchange Commission.

Apnimed Company Profile

(Get Free Report)

Apnimed is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies. Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment.

Recommended Stories

Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.